CA
NZ
UK
AU
IND
US
…
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Centene Corporation is a diversified managed care company that administers government-sponsored health plans—mainly Medicaid, Medicare Advantage and ACA marketplace products—along with pharmacy, behavioral health and other specialty services. Long-term growth could be supported by demographic trends, Medicaid expansion, rising Medicare Advantage enrollment and scale-driven efficiency from its national footprint, which may appeal to investors seeking exposure to government-backed health coverage.
Key risks include material exposure to federal and state regulatory and reimbursement changes, execution and integration risk from acquisitions, and sensitivity of earnings to medical cost inflation.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -6727.96M | 4257.00M | 3598.00M | 1962.00M | 1813.00M |
| Minority interest | 3.00M | 11.00M | 3.00M | 3.00M | 11.00M |
| Net income | -6673.00M | 3305.00M | 2702.00M | 1202.00M | 1347.00M |
| Selling general administrative | 13263.38M | 12400.00M | 12273.00M | 20919.00M | 10166.00M |
| Gross profit | 23833.44M | 16829.00M | 31541.00M | 16656.00M | 14199.00M |
| Reconciled depreciation | 1275.00M | 1241.00M | 1452.00M | 1553.00M | 1476.00M |
| Ebit | -6415.38M | 4959.00M | 2930.00M | 2627.00M | 2478.00M |
| Ebitda | -5140.38M | 6200.00M | 2930.00M | 4058.00M | 3954.00M |
| Depreciation and amortization | 1275.00M | 1241.00M | 1293.00M | 1431.00M | 1476.00M |
| Non operating income net other | - | - | - | 1279.00M | 819.00M |
| Operating income | -7618.38M | 3175.00M | 2930.00M | 3636.00M | 3263.00M |
| Other operating expenses | 202395.38M | 159896.00M | 151069.00M | 140911.00M | 122719.00M |
| Interest expense | 678.00M | 702.00M | 725.00M | 665.00M | 665.00M |
| Tax provision | -51.00M | 963.00M | 1174.00M | 760.00M | 477.00M |
| Interest income | 678.00M | 702.00M | - | 665.00M | 665.00M |
| Net interest income | -678.00M | -702.00M | -716.00M | -665.00M | -665.00M |
| Extraordinary items | 4.00M | - | - | - | - |
| Non recurring | - | - | - | 2318.00M | 1479.00M |
| Income tax expense | -50.96M | 963.00M | 899.00M | 760.00M | 477.00M |
| Total revenue | 194777.00M | 163071.00M | 153999.00M | 144547.00M | 125982.00M |
| Total operating expenses | 31451.81M | 13654.00M | 28611.00M | 13020.00M | 10936.00M |
| Cost of revenue | 170943.56M | 146242.00M | 122458.00M | 127891.00M | 111783.00M |
| Total other income expense net | 890.41M | 1082.00M | 668.00M | 644.00M | 29.00M |
| Net income from continuing ops | -6677.00M | 3294.00M | 2441.00M | 1202.00M | 1336.00M |
| Net income applicable to common shares | -6674.00M | 3305.00M | - | 1202.00M | 1347.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 77661.00M | 82445.00M | 84641.00M | 76870.00M | 78375.00M |
| Intangible assets | 4530.00M | 5409.00M | 6101.00M | 6911.00M | 7824.00M |
| Other current assets | 20050.00M | 1601.00M | 21104.00M | 2461.00M | 1602.00M |
| Total liab | 57605.00M | 55935.00M | 58685.00M | 52633.00M | 51353.00M |
| Total stockholder equity | 19953.00M | 26410.00M | 25840.00M | 24057.00M | 26795.00M |
| Other current liab | -50.00M | 20316.00M | 19294.00M | 18379.00M | 16571.00M |
| Common stock | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Capital stock | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Retained earnings | 8674.00M | 15348.00M | 12043.00M | 9341.00M | 8139.00M |
| Other liab | - | - | - | 3098.00M | 7017.00M |
| Good will | 10835.00M | 17558.00M | 17558.00M | 18812.00M | 19771.00M |
| Other assets | 1940.00M | 1624.00M | - | 1217.00M | 4849.00M |
| Cash | 17888.00M | 14063.00M | 17193.00M | 12074.00M | 13118.00M |
| Cash and equivalents | 17888.00M | 14063.00M | - | 12074.00M | 13118.00M |
| Total current liabilities | 21476.00M | 34261.00M | 36716.00M | 28464.00M | 25765.00M |
| Current deferred revenue | 736.00M | 661.00M | 715.00M | 478.00M | 434.00M |
| Net debt | 889.00M | 5366.00M | 1684.00M | 5946.00M | 5720.00M |
| Short term debt | 196.00M | 268.00M | 287.00M | 82.00M | 267.00M |
| Short long term debt | 50.00M | 110.00M | 119.00M | 82.00M | 267.00M |
| Short long term debt total | 18777.00M | 19429.00M | 18877.00M | 18020.00M | 18838.00M |
| Other stockholder equity | 11336.00M | 11565.00M | 14448.00M | 15847.00M | 18578.00M |
| Property plant equipment | 2037.00M | 2426.00M | - | 2432.00M | 3391.00M |
| Total current assets | 35993.00M | 37999.00M | 40756.00M | 30128.00M | 28497.00M |
| Long term investments | 17035.00M | 17429.00M | 16286.00M | 14684.00M | 14043.00M |
| Net tangible assets | - | - | - | -1610.00M | -800.00M |
| Short term investments | 2432.00M | 2622.00M | 2459.00M | 2321.00M | 1539.00M |
| Net receivables | 18105.00M | 19713.00M | 15532.00M | 13272.00M | 12238.00M |
| Long term debt | 17351.00M | 18423.00M | 17710.00M | 17938.00M | 18571.00M |
| Inventory | - | - | -35184.00M | - | - |
| Accounts payable | 20544.00M | 13016.00M | 16252.00M | 9525.00M | 8493.00M |
| Noncontrolling interest in consolidated entity | - | - | - | 124.00M | 145.00M |
| Accumulated other comprehensive income | -58.00M | -504.00M | -652.00M | -1132.00M | 77.00M |
| Common stock total equity | - | - | - | 1.00M | 1.00M |
| Retained earnings total equity | - | - | - | 9341.00M | 8139.00M |
| Treasury stock | - | - | - | -4213.00M | -1094.00M |
| Non currrent assets other | 2156.00M | 1624.00M | 1525.00M | 3903.00M | 4849.00M |
| Non current assets total | 41668.00M | 44446.00M | 43885.00M | 46742.00M | 49878.00M |
| Capital lease obligations | 761.00M | 896.00M | 1048.00M | 3313.00M | - |
| Long term debt total | 17351.00M | 18423.00M | - | 17938.00M | 18571.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 1239.00M | -1052.00M | -21.00M | -2921.00M | -3299.00M |
| Change to liabilities | - | - | - | 3660.00M | 1032.00M |
| Total cashflows from investing activities | 453.00M | -1052.00M | - | -2921.00M | -3299.00M |
| Net borrowings | -1145.00M | 678.00M | - | -1144.00M | 1833.00M |
| Total cash from financing activities | -1602.00M | -2406.00M | -1658.00M | -4197.00M | 1362.00M |
| Change to operating activities | - | - | - | 3369.00M | 2797.00M |
| Net income | -6677.00M | 3294.00M | 2702.00M | 1202.00M | 1336.00M |
| Change in cash | 3825.00M | -3130.00M | 5122.00M | -884.00M | 2257.00M |
| Begin period cash flow | 14156.00M | 17193.00M | 12330.00M | 13214.00M | 10957.00M |
| End period cash flow | 17957.00M | 14063.00M | 17452.00M | 12330.00M | 13214.00M |
| Total cash from operating activities | 5088.00M | 154.00M | 8053.00M | 6261.00M | 4205.00M |
| Issuance of capital stock | 37.00M | 46.00M | 40.00M | 70.00M | 35.00M |
| Depreciation | 1275.00M | 1241.00M | 1293.00M | 1553.00M | 1476.00M |
| Other cashflows from investing activities | 1239.00M | 990.00M | - | -1917.00M | 19.00M |
| Dividends paid | - | - | 88.00M | - | 35.00M |
| Change to inventory | - | - | 2122.00M | - | -1141.00M |
| Change to account receivables | 1480.00M | -4333.00M | -2380.00M | -1627.00M | -2453.00M |
| Sale purchase of stock | -475.00M | -3124.00M | -1633.00M | -3096.00M | -297.00M |
| Other cashflows from financing activities | -19.00M | -6.00M | -88.00M | -41.00M | -174.00M |
| Change to netincome | - | - | - | 1314.00M | 6.00M |
| Capital expenditures | 767.00M | 644.00M | 799.00M | 1004.00M | 910.00M |
| Change receivables | - | - | - | -1627.00M | -2453.00M |
| Cash flows other operating | - | - | - | 159.00M | -208.00M |
| Cash and cash equivalents changes | - | - | - | -857.00M | 2268.00M |
| Change in working capital | 823.00M | -4515.00M | 3374.00M | 2194.00M | 1376.00M |
| Stock based compensation | 204.00M | 212.00M | 216.00M | 234.00M | 203.00M |
| Other non cash items | 9523.00M | -91.00M | 546.00M | 1709.00M | -54.00M |
| Free cash flow | 4321.00M | -490.00M | 7254.00M | 5257.00M | 3295.00M |
Sector: Healthcare Industry: Healthcare Plans
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CNC Centene Corp |
1.57 2.34% |
68.62 | - | 12.85 | 0.11 | 0.94 | 0.09 | 3.79 |
| UNH UnitedHealth Group Incorporated |
3.81 0.94% |
410.91 | 22.57 | 18.38 | 1.33 | 5.65 | 1.38 | 13.97 |
| CVS CVS Health Corp |
0.38 0.42% |
90.33 | 55.65 | 10.80 | 0.25 | 1.32 | 0.42 | 17.09 |
| ELV Elevance Health Inc |
7.61 1.84% |
422.02 | 18.47 | 14.58 | 0.45 | 2.05 | 0.56 | - |
| CI Cigna Corp |
3.41 1.16% |
298.41 | 11.94 | 8.68 | 0.27 | 1.80 | 0.36 | 7.93 |
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
| Name | Title | Year Born |
|---|---|---|
| Ms. Sarah M. London | Chief Exec. Officer & Director | 1981 |
| Mr. Brent Davis Layton | Pres & COO | 1968 |
| Mr. Andrew Lynn Asher | Exec. VP & CFO | 1969 |
| Mr. Christopher Andrew Koster | Exec. VP, Gen. Counsel & Sec. | 1965 |
| Mr. Michael Frederic Neidorff | Chairman (Leave of Absence) | 1943 |
| Ms. Katie Nicole Casso | Sr. VP, Chief Accounting Office & Corp. Controller | 1982 |
| Mr. Mark J. Brooks | Exec. VP & Chief Information Officer | 1970 |
| Ms. Shannon Bagley | Exec. VP & Chief Admin. Officer | 1979 |
| Ms. Jennifer Lynch Gilligan | Sr. VP of Investor Relations | NA |
| Ms. Ashlee Knuckey | Chief Ethics & Compliance Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.50%
Communication Services
+0.29%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
-0.00%
Financial Services
+0.64%
Financials
-2.62%
Healthcare
+0.50%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.35%
Utilities
+0.51%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...